Alzheimer’s drug gets FDA support for its ability to slow disease


IE 11 is not supported. For an optimal experience visit our site on another browser.

  • Now Playing

    FDA panel votes to endorse Alzheimer’s drug from Eli Lilly

    02:51

  • UP NEXT

    Keep your fitness goals on track with these tips from Ally Love

    05:16

  • How to protect yourself from the heat, ticks, more this summer

    05:01

  • What to do if someone is choking, bleeding or needs CPR

    05:22

  • Is sugar the new cigarettes? Why you may see new warning labels

    03:58

  • Dietitian shares smart ways to make the best use fruits this summer

    05:03

  • Why it may be dangerous to drink alcohol before napping on a flight

    02:43

  • Start TODAY challenge for June 2024: Love where you walk

    04:50

  • Al Roker reports from the sidelines for 15th anniversary of Big Slick

    05:33

  • Why do we dream and have nightmares, and what do they mean?

    05:17

  • TODAY’s Five Things: Doctors share top advice for women’s health

    08:24

  • Why are young, healthy adults experiencing a rise in heart attacks?

    03:38

  • Value wars: Walgreens is latest retailer set to lower prices

    02:37

  • How to make healthier choices when it comes to cheese

    05:16

  • Simple swaps to help you streamline in your morning routine

    03:53

  • Christie Brinkley opens up about skin cancer diagnosis on TODAY

    05:54

  • Statins linked to lower risk for cardiovascular disease and death

    02:06

  • Meet the wellness advocate creating safe spaces for women

    04:54

  • Marine veteran donates kidney to his billiards rival

    04:33

  • Second human case of bird flu linked to dairy cows in Michigan

    00:22

A panel from the FDA has backed Eli Lilly’s donanemab for its ability to slow the early progression of Alzheimer’s, paving the way for the treatment to be fully approved in the U.S. later in the year. NBC’s Dr. Tara Narula breaks down how the drug works on TODAY.



Source link